The mycotoxins citrinin and gliotoxin differentially affect production of the pro-inflammatory cytokines tumour necrosis factor-α and interleukin-6, and the anti-inflammatory cytokine interleukin-10

Clinical and Experimental Allergy

Volumn 35, Issue 6, 2005, Pages 782-789

  Johannessen, Lene N ^a   Nilsen, A M ^a   Lovik M ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

IL 10; IL 6; Indoor air; Mycotoxins; TNF

Indexed keywords

CITRININ; GLIOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYCOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

AMBIENT AIR; APOPTOSIS; ARTICLE; ASTHMA; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; MOULD; PRIORITY JOURNAL; SUPERNATANT;

AIR POLLUTION, INDOOR; ANTI-BACTERIAL AGENTS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CITRININ; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GLIOTOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MONOCYTES; RESPIRATORY HYPERSENSITIVITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21844464337     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02249.x     Document Type: Article

References (51)

1. Peat JK, Dickerson J, Li J. Effects of damp and mould in the home on respiratory health: a review of the literature. Allergy 1998; 53:120-8.
2. Norbäck D, Björnsson E, Janson C, Palmgren U, Boman G. Current asthma and biochemical signs of inflammation in relation to building dampness in dwellings. Int J Tuberculosis Lung Dis 1999; 3:368-76.
3. Kilpeläinen M, Terho EO, Helenius H, Koskenvuo M. Home dampness, current allergic diseases, and respiratory infections among young adults. Thorax 2001; 56:462-7.
4. Zock JP, Jarvis D, Luczynska C, Sunyer J, Burney P. Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey. J Allergy Clin Immunol 2002; 110:285-92.
5. Terr AI. Are indoor molds causing a new disease? J Allergy Clin Immunol 2004; 113:221-6.
6. Santilli J, Rockwell W. Fungal contamination of elementary schools: a new environmental hazard. Ann Allergy Asthma Immunol 2003; 90:203-8.
7. Douwes J, Pearce N. Invited commentary: is indoor mold exposure a risk factor for asthma? Am J Epidemiol 2003; 158:203-6.
8. Gent JF, Ren P, Belanger K et al. Levels of household mold associated with respiratory symptoms in the first year of life in a cohort at risk for asthma. Environ Health Perspect 2002; 110:A781-6.
9. Thorn J. The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflamm Res 2001; 50:254-61.
10. Rylander R, Rong-Hwa L. (1 → 3)-β-D-glucan - relationship to indoor air-related symptoms, allergy and asthma. Toxicology 2000; 152:47-52.
11. Beijer L, Thorn J, Rylander R. Effects after inhalation of (1 → 3)-β-D-glucan and relationship to mould exposure in the home. Mediators Inflamm 2002; 11:149-53.
12. Beijer L, Thorn J, Rylander R. Mould exposure at home relates to inflammatory markers in blood. Eur Respir J 2003; 21:317-22.
13. Mari A, Schneider P, Wally V, Breitenbach M, Simon-Nobbe B. Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts. Clin Exp Allergy 2003; 33: 1429-38.
14. Kreja L, Seidel HJ. Evaluation of the genotoxic potential of some microbial volatile organic compounds (MVOC) with the comet assay, the micronucleus assay and the HPRT gene mutation assay. Mutat Res 2002; 513:143-50.
15. Fischer G, Dott W. Relevance of airborne fungi and their secondary metabolites for environmental, occupational and indoor hygiene. Arch Microbiol 2003; 179:75-82.
16. Bunger J, Westpal G, Monnich A, Hinnendahl B, Hallier E, Muller M. Cytotoxicity of occupationally and environmentally relevant mycotoxins. Toxicology 2004; 202:199-211.
17. Schulz T, Senkpiel K, Ohgke H. Comparison of the toxicity of reference mycotoxins and spore extracts of common indoor moulds. Int J Hyg Environ Health 2004; 207:267-77.
18. Fog Nielsen K. Mycotoxin production by indoor molds. Fungal Genet Biol 2003; 39:103-17.
19. Pavlovic M. Toxic effects of mycotoxins in humans. Bull World Health Organ 1999; 77:754-66.
20. Robbins CA, Swenson LJ, Nealley ML, Gots RE, Kelman BJ. Health effects of mycotoxins in indoor air: a critical review. Appl Occup Environ Hygiene 2000; 15:773-84.
21. Watanabe A, Kamei K, Sekine T et al. Effect of aeration on gliotoxin production by Aspergillus fumigatus in its culture filtrate. Mycopathologia 2004; 157:245-54.
22. Belkacemi L, Barton RC, Hopwood V, Evans EG. Determination of optimum growth conditions for gliotoxin production by Aspergillus fumigatus and development of a novel method for gliotoxin detection. Med Mycol 1999; 37:227-33.
23. Nieminen SM, Karki R, Auriola S et al. Isolation and identification of Aspergillus fumigatus mycotoxins on growth medium and some building materials. Appl Environ Microbiol 2002; 68:4871-5.
24. Tuomi T, Reijula K, Johnsson T et al. Mycotoxins in crude building materials from water-damaged buildings. Appl Environ Microbiol 2000; 66:1899-904.
25. Ziegler-Heitbrock HW, Thiel E, Fütterer A, Herzog V, Wirtz A, Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41:456-61.
26. Oshiro Y, Morris DL. TNF-alpha release from human peripheral blood mononuclear cells to predict the proinflammatory activity of cytokines and growth factors. J Pharmacol Toxicol Methods 1997; 37:55-9.
27. Sánchez-Del-Rio M, Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 2004; 17:289-93.
28. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10:2327-34.
29. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12:141-79.
30. Umezawa K, Ariga A, Matsumoto N. Naturally occurring and synthetic inhibitors of NF-kappaB functions. Anticancer Drug Des 2000; 15:239-44.
31. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-90.
32. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151:6853-61.
33. Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol 1997; 158:3673-81.
34. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
35. Sato S, Nomura F, Kawai T et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 2000; 165:7096-101.
36. Bellocchio S, Montagnoli C, Bozza S et al. The contribution of the toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004; 172:3059-69.
37. Wang JE, Warris A, Ellingsen EA et al. Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001; 69:2402-6.
38. Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003; 5:561-70.
39. Braedel S, Radsak M, Einsele H et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol 2004; 125:392-9.
40. Fernandez S, Jose P, Avdiushko MG, Kaplan AM, Cohen DA. Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists. J Immunol 2004; 172:2613-20.
41. Leemans JC, Vervoordeldonk MJ, Florquin S, van Kessel KP, van der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 2002; 165: 1445-50.
42. Dube PH, Handley SA, Lewis J, Miller VL. Protective role of interleukin-6 during Yersinia enterocolitica infection is mediated through the modulation of inflammatory cytokines. Infect Immun 2004; 72:3561-70.
43. Wichmann G, Herbarth O, Lehmann I. The mycotoxins citrinin, gliotoxin, and patulin affect interferon-gamma rather than interleukin-4 production in human blood cells. Environ Toxicol 2002; 17:211-8.
44. Liu Y, Zhang J, Zhao Z, Ling Y. Pro-apoptotic role of NF-kappaB pathway inhibition in lipopolysaccharide-stimulated polymorphonuclear neutrophils. Chin Med J (Engl) 2003; 116:1257-61.
45. Plümpe J, Malek NP, Bock CT, Rakemann T, Manns MP, Trautwein C. NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration 2000; 278:0173-83.
46. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol 2003; 39:38-46.
47. Pahl HL, Krauss B, Schulze-Osthoff K et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med 1996; 183:1829-40.
48. Sutton P, Newcombe NR, Waring P, Müllbacher A. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun 1994; 62:1192-8.
49. Ward C, Chilvers ER, Lawson MF et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem 1999; 274:4309-18.
50. Waring P, Eichner RD, Müllbacher A, Sjaarda A. Gliotoxin induces apoptosis in macrophages unrelated to its antiphagocytic properties. J Biol Chem 1988; 263:18493-9.
51. Ueno Y, Umemori K, Niimi E et al. Induction of apoptosis by T-2 toxin and other natural toxins in HL-60 human promyelotic leukemia cells. Nat Toxins 1995; 3:129-37.